Development of drugs in public-private partnership (PPP) environments
•Download as PPT, PDF•
1 like•887 views
The document discusses public-private partnerships (PPPs) for drug development, specifically for orphan and neglected diseases. It outlines the traditional private drug development process, challenges of developing drugs for diseases that do not have large patient populations able to pay, and how PPPs aim to address this by bringing together public and private sector expertise and resources. One example of a PPP, Bayer's Grants4Targets program, provides early-stage research funding for academic scientists while allowing them to retain intellectual property rights. The document raises debates around ensuring PPPs are effective and that resulting drugs are accessible to those in need.
Report
Share
Report
Share
![Agenda 15-min slides + 10-min debate ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
IMS Health Workshop World Orphan Drug Congress
This document provides an agenda for a workshop titled "Using real-world data to find undiagnosed patients with rare diseases" hosted by IMS Health at the World Orphan Drug Congress from April 20-22 in Washington D.C. The workshop will explore how real-world data can help address underdiagnosis of rare diseases. Speakers will discuss using large-scale real-world data to transform understanding of rare diseases, and present case studies of companies leveraging real-world data. The workshop will also cover using predictive modeling of real-world data to identify undiagnosed rare disease patients and new engagement models with healthcare providers and payers to increase rare disease treatments.
Diagnostics 2011-full-report
M&A deal values in the in vitro diagnostics sector surged in 2010 to $4.7 billion, driven by five factors including private equity returning to the sector and medical technology companies combining with diagnostics businesses. While the number of deals remained flat at around 45 deals, the market shares of top players are expected to reshuffle following mega-deals by Danaher and Thermo Fisher in 2011 that are projected to more than triple the total M&A value for the year. New market entrants will continue to reshape the competitive landscape through 2015 as historical leaders respond to avoid losing industry rank.
How predictive analytics can help find the rare disease patient
This document discusses how predictive analytics using real-world data can help identify undiagnosed rare disease patients. It describes two case studies: 1) A screening algorithm identified potentially undiagnosed patients for a rare multi-system disease with a high risk prevalence of 20.5% compared to 0.7% of the population. 2) An analysis of a rare cardiac disease identified health system barriers like variability between diagnostic centers that could cause under diagnosis. While initial results are promising, challenges remain around data privacy, sample size, and clinician adoption of screening algorithms.
Natalie Rebeyev rare disease nurse network crdn summit 2017
The document discusses the potential for a telemedicine pilot program to serve patients with rare diseases. It summarizes surveys that found over 50% of patients would be receptive to telemedicine and over 90% are willing to learn video call applications. The document estimates a 3-year pilot program could save £6.8 million in healthcare costs while costing approximately £975,000 to implement. Key operational requirements for the pilot include videoconferencing capabilities and secure data protection.
The usability of STAMP in drug development
Arete-Zoe in cooperation with Stuttgart University
Study authors: Veronika Valdova, Ronald L Sheckler, Asim Abdulkhaleq and Stefan Wagner (Jonathan M Fishbein)
Presentation of synopsis: Veronika Valdova
Presented at STAMP team meeting, PSCI, ACRES on February 26, 2016
Decentralized trials white paper by Andaman7
- Mobile clinical trials offer advantages over traditional trials such as improved data collection, simplified recruitment, and increased patient engagement.
- A study found that 76% of respondents would prefer to participate in a mobile clinical trial rather than a traditional one.
- Mobile technologies are revolutionizing clinical research by facilitating access to information, enabling more patients to participate regardless of location, and allowing for more convenient participation.
Predictive modeling healthcare
Presentation on Predictive modeling in Health-care at San Jose, Ca 2015. This presentation talks about healthcare industry in US, provides stats and forecasts. It then discusses a few use cases in health care and goes into detail on a kaggle example.
MNM COVID-19 Study
Repurposed existing drugs and updated global health policy and clinical guidelines will be essential for limiting the social and economic devastation caused by this virus. So, we are leading a three-phase multinational Network Medicine clinical study (MNM COVID-19 study). The study will apply Network Medicine methodologies to repurpose existing drugs for SARS-CoV-2 infected patients and update global health policy and clinical guidelines.
Recommended
IMS Health Workshop World Orphan Drug Congress
This document provides an agenda for a workshop titled "Using real-world data to find undiagnosed patients with rare diseases" hosted by IMS Health at the World Orphan Drug Congress from April 20-22 in Washington D.C. The workshop will explore how real-world data can help address underdiagnosis of rare diseases. Speakers will discuss using large-scale real-world data to transform understanding of rare diseases, and present case studies of companies leveraging real-world data. The workshop will also cover using predictive modeling of real-world data to identify undiagnosed rare disease patients and new engagement models with healthcare providers and payers to increase rare disease treatments.
Diagnostics 2011-full-report
M&A deal values in the in vitro diagnostics sector surged in 2010 to $4.7 billion, driven by five factors including private equity returning to the sector and medical technology companies combining with diagnostics businesses. While the number of deals remained flat at around 45 deals, the market shares of top players are expected to reshuffle following mega-deals by Danaher and Thermo Fisher in 2011 that are projected to more than triple the total M&A value for the year. New market entrants will continue to reshape the competitive landscape through 2015 as historical leaders respond to avoid losing industry rank.
How predictive analytics can help find the rare disease patient
This document discusses how predictive analytics using real-world data can help identify undiagnosed rare disease patients. It describes two case studies: 1) A screening algorithm identified potentially undiagnosed patients for a rare multi-system disease with a high risk prevalence of 20.5% compared to 0.7% of the population. 2) An analysis of a rare cardiac disease identified health system barriers like variability between diagnostic centers that could cause under diagnosis. While initial results are promising, challenges remain around data privacy, sample size, and clinician adoption of screening algorithms.
Natalie Rebeyev rare disease nurse network crdn summit 2017
The document discusses the potential for a telemedicine pilot program to serve patients with rare diseases. It summarizes surveys that found over 50% of patients would be receptive to telemedicine and over 90% are willing to learn video call applications. The document estimates a 3-year pilot program could save £6.8 million in healthcare costs while costing approximately £975,000 to implement. Key operational requirements for the pilot include videoconferencing capabilities and secure data protection.
The usability of STAMP in drug development
Arete-Zoe in cooperation with Stuttgart University
Study authors: Veronika Valdova, Ronald L Sheckler, Asim Abdulkhaleq and Stefan Wagner (Jonathan M Fishbein)
Presentation of synopsis: Veronika Valdova
Presented at STAMP team meeting, PSCI, ACRES on February 26, 2016
Decentralized trials white paper by Andaman7
- Mobile clinical trials offer advantages over traditional trials such as improved data collection, simplified recruitment, and increased patient engagement.
- A study found that 76% of respondents would prefer to participate in a mobile clinical trial rather than a traditional one.
- Mobile technologies are revolutionizing clinical research by facilitating access to information, enabling more patients to participate regardless of location, and allowing for more convenient participation.
Predictive modeling healthcare
Presentation on Predictive modeling in Health-care at San Jose, Ca 2015. This presentation talks about healthcare industry in US, provides stats and forecasts. It then discusses a few use cases in health care and goes into detail on a kaggle example.
MNM COVID-19 Study
Repurposed existing drugs and updated global health policy and clinical guidelines will be essential for limiting the social and economic devastation caused by this virus. So, we are leading a three-phase multinational Network Medicine clinical study (MNM COVID-19 study). The study will apply Network Medicine methodologies to repurpose existing drugs for SARS-CoV-2 infected patients and update global health policy and clinical guidelines.
Life Sciences Trends 2014
2014 Overview of significant trends in the life sciences (Biotechnology, Pharmaceutical, Device and Diagnostics) industry with Big Data in the Life Sciences featured articles.
Healthcare and Management Predictions 2020 by Dr.Mahboob Khan Phd
In this report we set out ten provocative statements predicting the world of 2020. Each prediction is articulated and brought to life through a series of portraits which imagine how patients, healthcare professionals and life sciences organizations might behave in this new world. Our predictions lean more towards an optimistic view of the future, although we organized that many in our industry are organized about the constraints and therefore pace of change. We describe the big trends rolled forward to 2020 and some of the constraints that will need to be overcome.
We also provide examples and evidence, based on the here and now, that show that the predictions are perfectly plausible, perhaps inspiring and surprising!
Our industry is changing quickly – requiring a bold response that is often difficult to implement – and yet organizations struggle to understand how to respond effectively and build a sense of urgency. We hope this report creates rich dialogue and enables a move to action.– we have had enormous fun discussing these predictions and sharing our experiences. We hope you have the same experience within your own organizations as you peruse this report and reflect on your current situation and future scenarios.
Searching socialmediaforadverseevents
Dr. Su Golder, NIHR Research Fellow at the University of York, presents findings from her recent publication: “Systematic review on the prevalence, frequency and comparative value of adverse events data in social media”.
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
This document provides information about the 6th Annual Global Orphan Drug Conference and Expo taking place April 21-22, 2016 in Washington D.C. The conference will bring together stakeholders in the orphan drug industry including pharmaceutical companies, patient advocacy groups, regulators, payers, and investors. It will include keynote sessions, workshops on topics like market forecasting and commercialization, and networking opportunities. A pre-conference day of workshops is scheduled for April 20th.
COVID19| What's next
Viruses mutate over time as such governments around the world need to be vigilant when it comes to their mitigation steps for any viruses.
Day 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation Conference
Day 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation ConferenceCanadian Organization for Rare Disorders
Why Precision Medicine and Personalized Healthcare and Why Now? Links to Canada’s Rare Disease Strategy The Future is Now
1) Marc LePage, Genome Canada
2) Michael Duong, Roche
3) Danica Stanimirovic, National Research Council
4) Daniel Gaudet, University of Montreal
5) Christine Dalgleish, Patient Perspective
6) Jamie Bruce, Khure Health
Prescription Medicines - Costs in Context - September 2018
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
Federal Election Special - What are the Parties Saying About Healthcare and C...
Federal Election Special - What are the Parties Saying About Healthcare and C...Canadian Cancer Survivor Network
The document summarizes the federal parties' stances on health and oncology policy based on their responses to questions from the Canadian Cancer Survivor Network (CCSN). The Conservative Party had not yet provided any answers. The Liberal Party, NDP, and Bloc Quebecois provided responses supporting expanding employment insurance sickness benefits, improving access to disability benefits, and working with provinces on a national pharmacare program. The Liberal Party and NDP emphasized increasing healthcare funding and leadership. The Green Party had not yet responded.Prescription Medicines - Costs in Context - September 2018
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
Clinical Research Informatics Year-in-Review 2021
Keynote presentation: Clinical Research Informatics & Implementation Science Year-in-Review, presented at the AMIA Informatics Summit, 2021
Promise and peril: How artificial intelligence is transforming health care
AI has enormous potential to improve the quality of health care, enable early diagnosis of diseases, and reduce costs. But if implemented incautiously, AI can exacerbate health disparities, endanger patient privacy, and perpetuate bias. STAT, with support from the Commonwealth Fund, explored these possibilities and pitfalls during the past year and a half, illuminating best practices while identifying concerns and regulatory gaps. This report includes many of the articles we published and summarizes our findings, as well as recommendations we heard from caregivers, health care executives, academic experts, patient advocates, and others.
9a Alves Pharma
The document discusses concerns about drug promotion and its impact on the rational use of medicines. It notes that less than half of countries effectively regulate drug promotion and most rely on industry self-regulation. The document also provides several examples of misleading or unsubstantiated drug advertising from different countries. It concludes that public health and welfare should come before industry interests and that patients need unbiased information on treatment options instead of disguised advertising.
Hellenic Innovation Forum, Γιώργος Κλέτσας
Ομιλία - Παρουσίαση:
Γιώργος Κλέτσας, Manager, Technology, Greece & Balkans, QuintilesIMS
«Σχεδιάζοντας την αντιμετώπιση των επιδημιών γρίπης πιο αξιόπιστα»
Hellenic Innovation Forum, Matti Arvela
Ομιλία - Παρουσίαση Δημοσκόπησης Alco:
Matti Arvela, Member of PhRMA Innovation Forum, Executive Director and General Manager, Amgen Hellas and Cyprus
Top 4 global trends in life science and healthcare and why is this important ...
Top Global Trend Areas of Scientific advancements in Life Science and Healthcare
How Middle Eastern Healthcare Ecosystem can Benefit for these Advancement
Challenges to improve medicines transparency in Ghana
This is a presentation by Dr Daniel Kojo Arhinful at the launch of the Medicines Transparency Alliance (MeTA) in Ghana in November 2008. MeTA is a global alliance, working in 7 pilot countries. For more information, see www.MedicinesTransparency.org
EuroBioForum 2013 - Day 2 | Mark Poznansky
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# REGIONAL PERSPECTIVES #
Ontario Genomics Institute, Canada:
Innovative Research, Innovative Translation
Dr Mark Poznansky
President and CEO Ontario Genomics Institute
=======================================
http://www.eurobioforum.eu
Clinical Research Informatics Year-in-Review
Peter Embi's 2018 Clinical Research Informatics Year-in-Review. Presented as closing Keynote address at the 2018 AMIA Informatics Summit in San Francisco, CA.
ARTIFICIAL Intelligence IN INFECTIOUS DISEASES
The document discusses the use of artificial intelligence in infectious diseases. It describes how AI can help monitor infectious disease processes through tools like electronic health records. AI has the potential to help address public health concerns in infectious diseases by more quickly tracking outbreaks and optimizing detection and control of diseases. The document outlines how AI may help create smarter health systems and reduce costs associated with infectious diseases.
Rare Cancers - How to Empower Patients & Advocacy Organizations through Colla...
Rare Cancers - How to Empower Patients & Advocacy Organizations through Colla...Canadian Cancer Survivor Network
The document discusses collaboration between patient advocacy organizations for rare cancers in Canada. It summarizes discussions from a panel on empowering patients which included representatives from Myeloma Canada, GIST Sarcoma Life Raft Group Canada, and the Canadian Organization for Rare Disorders. The panel addressed issues for rare cancers around definitions, impact vs attention and research, screening, access to specialists, regulatory challenges, treatment pathways, and opportunities for the rare cancers community to work together.GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...
Every day, Non Governmental Organization NGOs is confronted with the lack of access to adequate or affordable medical tools in the field. They face two major challenges the high cost of existing medicines on the one hand, and the absence of appropriate or effective treatments for many of the diseases affecting our patients on the other, we are talking about Neglected Tropical Disease NTD in the Least developed Countries LDCs.
Andrew Witty, Chief Executive Officer of Glaxo Smith Klein (GSK) delivered a speech at the Harvard Business School in Boston on February 2009 entitled “Big pharma a catalyst for Change” focused on two issues: a) promoting innovation to prevent or treat NTDs in the world’s Least Developed Countries by creating a “pharmaceutical patent pool”; b) improving the access to medicine in the poorer countries by lowering the prices of GSK’s medicines.
In deed, we are assisting a radical change in pharma Business model, we are moving from conflict to collaboration through the Medicines Patent Pool in the hope that it speed up access to newer medicines, and boost initiatives that make use of alternative financing mechanisms in order to develop new, more appropriate treatments that respond to medical needs.
On the other hand the pricing strategy dilemma facing the generic manufacturers and the non inclusion of HIV which is a major neglected disease in LDCs in the patent pool may compromise the success of such business model.
In order to deal with that two issues, GSK should include HIV drugs in their patent pool as other manufacturers and NGO are doing, and concerning the pricing strategy they should emphasize on the high quality of the original drug mandatory to eradicate this NTDs and communicate more on the fact that GSK will invest 20% of these drugs profit to improve the infrastructure of these LDCs.
Project Management_DM Presentation
This document introduces the team and project for Media4Patient. The project aims to improve clinical trial enrollment through a new digital platform using social media and mobile technologies. It outlines challenges with patient recruitment such as many trials not reaching full enrollment and patients being unaware of clinical trial options. It then discusses stakeholders in clinical trials and viewpoints from different groups. Finally, it performs a PESTEL analysis to examine political, economic, technological, legal, environmental and socio-cultural factors affecting the project.
More Related Content
What's hot
Life Sciences Trends 2014
2014 Overview of significant trends in the life sciences (Biotechnology, Pharmaceutical, Device and Diagnostics) industry with Big Data in the Life Sciences featured articles.
Healthcare and Management Predictions 2020 by Dr.Mahboob Khan Phd
In this report we set out ten provocative statements predicting the world of 2020. Each prediction is articulated and brought to life through a series of portraits which imagine how patients, healthcare professionals and life sciences organizations might behave in this new world. Our predictions lean more towards an optimistic view of the future, although we organized that many in our industry are organized about the constraints and therefore pace of change. We describe the big trends rolled forward to 2020 and some of the constraints that will need to be overcome.
We also provide examples and evidence, based on the here and now, that show that the predictions are perfectly plausible, perhaps inspiring and surprising!
Our industry is changing quickly – requiring a bold response that is often difficult to implement – and yet organizations struggle to understand how to respond effectively and build a sense of urgency. We hope this report creates rich dialogue and enables a move to action.– we have had enormous fun discussing these predictions and sharing our experiences. We hope you have the same experience within your own organizations as you peruse this report and reflect on your current situation and future scenarios.
Searching socialmediaforadverseevents
Dr. Su Golder, NIHR Research Fellow at the University of York, presents findings from her recent publication: “Systematic review on the prevalence, frequency and comparative value of adverse events data in social media”.
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
This document provides information about the 6th Annual Global Orphan Drug Conference and Expo taking place April 21-22, 2016 in Washington D.C. The conference will bring together stakeholders in the orphan drug industry including pharmaceutical companies, patient advocacy groups, regulators, payers, and investors. It will include keynote sessions, workshops on topics like market forecasting and commercialization, and networking opportunities. A pre-conference day of workshops is scheduled for April 20th.
COVID19| What's next
Viruses mutate over time as such governments around the world need to be vigilant when it comes to their mitigation steps for any viruses.
Day 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation Conference
Day 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation ConferenceCanadian Organization for Rare Disorders
Why Precision Medicine and Personalized Healthcare and Why Now? Links to Canada’s Rare Disease Strategy The Future is Now
1) Marc LePage, Genome Canada
2) Michael Duong, Roche
3) Danica Stanimirovic, National Research Council
4) Daniel Gaudet, University of Montreal
5) Christine Dalgleish, Patient Perspective
6) Jamie Bruce, Khure Health
Prescription Medicines - Costs in Context - September 2018
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
Federal Election Special - What are the Parties Saying About Healthcare and C...
Federal Election Special - What are the Parties Saying About Healthcare and C...Canadian Cancer Survivor Network
The document summarizes the federal parties' stances on health and oncology policy based on their responses to questions from the Canadian Cancer Survivor Network (CCSN). The Conservative Party had not yet provided any answers. The Liberal Party, NDP, and Bloc Quebecois provided responses supporting expanding employment insurance sickness benefits, improving access to disability benefits, and working with provinces on a national pharmacare program. The Liberal Party and NDP emphasized increasing healthcare funding and leadership. The Green Party had not yet responded.Prescription Medicines - Costs in Context - September 2018
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
Clinical Research Informatics Year-in-Review 2021
Keynote presentation: Clinical Research Informatics & Implementation Science Year-in-Review, presented at the AMIA Informatics Summit, 2021
Promise and peril: How artificial intelligence is transforming health care
AI has enormous potential to improve the quality of health care, enable early diagnosis of diseases, and reduce costs. But if implemented incautiously, AI can exacerbate health disparities, endanger patient privacy, and perpetuate bias. STAT, with support from the Commonwealth Fund, explored these possibilities and pitfalls during the past year and a half, illuminating best practices while identifying concerns and regulatory gaps. This report includes many of the articles we published and summarizes our findings, as well as recommendations we heard from caregivers, health care executives, academic experts, patient advocates, and others.
9a Alves Pharma
The document discusses concerns about drug promotion and its impact on the rational use of medicines. It notes that less than half of countries effectively regulate drug promotion and most rely on industry self-regulation. The document also provides several examples of misleading or unsubstantiated drug advertising from different countries. It concludes that public health and welfare should come before industry interests and that patients need unbiased information on treatment options instead of disguised advertising.
Hellenic Innovation Forum, Γιώργος Κλέτσας
Ομιλία - Παρουσίαση:
Γιώργος Κλέτσας, Manager, Technology, Greece & Balkans, QuintilesIMS
«Σχεδιάζοντας την αντιμετώπιση των επιδημιών γρίπης πιο αξιόπιστα»
Hellenic Innovation Forum, Matti Arvela
Ομιλία - Παρουσίαση Δημοσκόπησης Alco:
Matti Arvela, Member of PhRMA Innovation Forum, Executive Director and General Manager, Amgen Hellas and Cyprus
Top 4 global trends in life science and healthcare and why is this important ...
Top Global Trend Areas of Scientific advancements in Life Science and Healthcare
How Middle Eastern Healthcare Ecosystem can Benefit for these Advancement
Challenges to improve medicines transparency in Ghana
This is a presentation by Dr Daniel Kojo Arhinful at the launch of the Medicines Transparency Alliance (MeTA) in Ghana in November 2008. MeTA is a global alliance, working in 7 pilot countries. For more information, see www.MedicinesTransparency.org
EuroBioForum 2013 - Day 2 | Mark Poznansky
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# REGIONAL PERSPECTIVES #
Ontario Genomics Institute, Canada:
Innovative Research, Innovative Translation
Dr Mark Poznansky
President and CEO Ontario Genomics Institute
=======================================
http://www.eurobioforum.eu
Clinical Research Informatics Year-in-Review
Peter Embi's 2018 Clinical Research Informatics Year-in-Review. Presented as closing Keynote address at the 2018 AMIA Informatics Summit in San Francisco, CA.
ARTIFICIAL Intelligence IN INFECTIOUS DISEASES
The document discusses the use of artificial intelligence in infectious diseases. It describes how AI can help monitor infectious disease processes through tools like electronic health records. AI has the potential to help address public health concerns in infectious diseases by more quickly tracking outbreaks and optimizing detection and control of diseases. The document outlines how AI may help create smarter health systems and reduce costs associated with infectious diseases.
Rare Cancers - How to Empower Patients & Advocacy Organizations through Colla...
Rare Cancers - How to Empower Patients & Advocacy Organizations through Colla...Canadian Cancer Survivor Network
The document discusses collaboration between patient advocacy organizations for rare cancers in Canada. It summarizes discussions from a panel on empowering patients which included representatives from Myeloma Canada, GIST Sarcoma Life Raft Group Canada, and the Canadian Organization for Rare Disorders. The panel addressed issues for rare cancers around definitions, impact vs attention and research, screening, access to specialists, regulatory challenges, treatment pathways, and opportunities for the rare cancers community to work together.What's hot (20)
Healthcare and Management Predictions 2020 by Dr.Mahboob Khan Phd
Healthcare and Management Predictions 2020 by Dr.Mahboob Khan Phd
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
Day 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation Conference
Day 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation Conference
Prescription Medicines - Costs in Context - September 2018
Prescription Medicines - Costs in Context - September 2018
Federal Election Special - What are the Parties Saying About Healthcare and C...
Federal Election Special - What are the Parties Saying About Healthcare and C...
Prescription Medicines - Costs in Context - September 2018
Prescription Medicines - Costs in Context - September 2018
Promise and peril: How artificial intelligence is transforming health care
Promise and peril: How artificial intelligence is transforming health care
Top 4 global trends in life science and healthcare and why is this important ...
Top 4 global trends in life science and healthcare and why is this important ...
Challenges to improve medicines transparency in Ghana
Challenges to improve medicines transparency in Ghana
Rare Cancers - How to Empower Patients & Advocacy Organizations through Colla...
Rare Cancers - How to Empower Patients & Advocacy Organizations through Colla...
Similar to Development of drugs in public-private partnership (PPP) environments
GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...
Every day, Non Governmental Organization NGOs is confronted with the lack of access to adequate or affordable medical tools in the field. They face two major challenges the high cost of existing medicines on the one hand, and the absence of appropriate or effective treatments for many of the diseases affecting our patients on the other, we are talking about Neglected Tropical Disease NTD in the Least developed Countries LDCs.
Andrew Witty, Chief Executive Officer of Glaxo Smith Klein (GSK) delivered a speech at the Harvard Business School in Boston on February 2009 entitled “Big pharma a catalyst for Change” focused on two issues: a) promoting innovation to prevent or treat NTDs in the world’s Least Developed Countries by creating a “pharmaceutical patent pool”; b) improving the access to medicine in the poorer countries by lowering the prices of GSK’s medicines.
In deed, we are assisting a radical change in pharma Business model, we are moving from conflict to collaboration through the Medicines Patent Pool in the hope that it speed up access to newer medicines, and boost initiatives that make use of alternative financing mechanisms in order to develop new, more appropriate treatments that respond to medical needs.
On the other hand the pricing strategy dilemma facing the generic manufacturers and the non inclusion of HIV which is a major neglected disease in LDCs in the patent pool may compromise the success of such business model.
In order to deal with that two issues, GSK should include HIV drugs in their patent pool as other manufacturers and NGO are doing, and concerning the pricing strategy they should emphasize on the high quality of the original drug mandatory to eradicate this NTDs and communicate more on the fact that GSK will invest 20% of these drugs profit to improve the infrastructure of these LDCs.
Project Management_DM Presentation
This document introduces the team and project for Media4Patient. The project aims to improve clinical trial enrollment through a new digital platform using social media and mobile technologies. It outlines challenges with patient recruitment such as many trials not reaching full enrollment and patients being unaware of clinical trial options. It then discusses stakeholders in clinical trials and viewpoints from different groups. Finally, it performs a PESTEL analysis to examine political, economic, technological, legal, environmental and socio-cultural factors affecting the project.
BioEntrepreneurship: The Business of Biotech
This is part of the MaRS BioEntrepreneurship series.
Speaker: Lynne Zydowsky, Ph.D., Managing Principal Zydowsky Consultants
* Explore the development of regulated drugs and devices
* Understand where and how value is generated in the pharmaceuticals industry
* Appreciate the interplay between science and business in a biotech company
To download a copy of the audio for this presentation, please go to:
http://www.marsdd.com/bioent/oct16
For the event blog and Q+A, please see:
http://blog.marsdd.com/2006/10/17/bringing-together-art-and-science/
Megafund for Rare Diseases
This document discusses the concept of "megafunds" to help fund research and development for rare diseases. It notes that current sources of funding like venture capital and philanthropic venture capital are not enough to develop treatments for the over 7,000 known rare diseases. It proposes creating large pooled investment funds or "megafunds" that would attract funding from institutional investors by issuing bonds or debt backed by the intellectual property of a portfolio of drug development programs. This could open access to a larger pool of capital to fund more rare disease research more efficiently and at a reduced risk level through diversification. It provides examples of past proposals and discussions around this concept as a potential new model to help bridge the "valley of death"
09 CeoMeeting- Session 4- Medicines for Malaria
The document discusses product development partnerships (PDPs) that work to develop medicines and treatments for diseases that disproportionately impact developing countries and have limited commercial incentives. It provides Medicine for Malaria Venture (MMV) as a key example of a PDP focused on developing antimalarial drugs. MMV has developed over a dozen antimalarial candidates and products over its existence, including a pediatric-friendly version of Coartem through partnerships with Novartis. PDPs have grown substantially over the past decade and play a central role in driving neglected disease product pipelines.
Stimulating Innovation, Improving Access
The Medicines Patent Pool Presentation during the session "Market Interventions for Innovation and Access", UN High Level Meeting on HIV/AIDS
New York, 9 June 2011
What's In An Idea-Chanda-UofT Life Science Coach
The document discusses challenges and opportunities in the medical innovation process. It notes that while regulatory approval and reimbursement processes can be slow, improvements are being made. Medical device innovation requires collaboration between physicians, engineers, and industry. The future includes more implanted diagnostics to better manage diseases and promote wellness. Overall, the field remains promising for new technologies despite barriers that can be further addressed.
IVD Market Size and Growth Trend
The document discusses the current state and expected growth trends of the in vitro diagnostics (IVD) market. It notes that the global IVD market was estimated at $54.2 billion in 2013 and is expected to grow 4% annually to $64.3 billion by 2018. Technological advances in areas like genomics, bioinformatics, and miniaturization have transformed diagnostic laboratory technology in recent years. Personalized medicine, infectious disease testing, and other applications are driving growth in the IVD market. However, economic instability, rising healthcare costs, and reimbursement changes pose challenges for the industry.
Delinkage oss2010 jameslove_kei
This document discusses proposals to de-link the costs of research and development from the prices of pharmaceutical products through the use of cash prizes and open source dividends rather than patents. It outlines several proposals for implementing such prize systems, including discussions at the WHO and proposals for specific disease areas. Key implementation challenges discussed include designing appropriate prize structures and managing open source dividend funds through competitive intermediaries.
CMT update 2014 fall
The document summarizes the work and goals of the Hereditary Neuropathy Foundation (HNF) in developing treatments for Charcot-Marie-Tooth (CMT) disease and related inherited neuropathies. HNF uses a collaborative model called TRIAD to bring discoveries from academic research into drug development through partnerships. Recent accomplishments include supporting the first Phase 3 clinical trial for CMT1A and funding research on models for CMT2A and other forms of CMT. HNF aims to establish a pipeline of treatments to bring early and late-stage options to clinical trials.
The Orphan Drug Act
The document summarizes the Orphan Drug Act of 1983 and its impact. It provides incentives like 7 years of marketing exclusivity and tax credits to stimulate development of drugs for rare diseases defined as affecting fewer than 200,000 people. Since 1983, over 1000 designations and 200 product approvals have occurred. While the Act has met its objectives, concerns around the high costs of orphan drugs and determining appropriate access and reimbursement are discussed.
A white paper on Collaborative Drug Discovery: The Rising Importance of Rare ...
A white paper on Tuberculosis, antimalarial dataset analysis, the state of drug discovery and beyond. Prepared for www.collaborativedrug.com.
Evolving markets require evolving market approaches
UNITAID's Brenda Waning Presentation at the UNITAID/UNAIDS/Medicines Patent Pool Side Event,
United Nations High Level Meeting on AIDS
New York
9 June, 2011
ClearView Orphan Drug White Paper
The document discusses opportunities and challenges for drug developers in the orphan disease space. It notes that while regulatory incentives and unmet medical need make orphan diseases attractive, drug developers must prepare for unique challenges such as lack of disease understanding, difficult patient identification and recruitment for clinical trials, and increasing restrictions from payers on pricing and access. Overall the orphan disease market remains an important area of focus for companies, but success will require strategies tailored to the complexities of these rare conditions.
info term paper final
This document summarizes a research paper analyzing asymmetric information between governments and pharmaceutical companies in R&D for drugs targeting neglected infectious diseases. It outlines push and pull strategies used by governments to incentivize private sector R&D. Under push strategies like grants, moral hazard arises as firms may divert funds to more profitable projects. The paper uses a principal-agent model to show that firms are better off diverting funds under push strategies. It suggests pull strategies that reward success may better align incentives.
Genentech
A presentation of Genentech strategic growth options vis-a-vis the current economic and structural challenges the biotech industry is facing.
Team project, December 2008.
Working in Global HealthChapter 18Chapter 18 Working i
There are many actors involved in global health working together towards common goals. Key actors include UN agencies like WHO and UNICEF, bilateral development agencies from countries, foundations, research funders, and NGOs. NGOs work on development programs, emergency relief, advocacy, and research. Partnerships have also formed around specific health issues like Roll Back Malaria to help coordinate efforts. Cooperation is important for setting standards, sharing knowledge, and finding global solutions to health challenges.
Drug Discovery, Development and Commercialization
its not my personal work presentation but taken from lecture ppt from university of San Diego, california.
Its about the drug discovery process, its development and its commercialization.
Cherian&Associates 10 Health Innovations
This document summarizes 10 health innovations and trends to watch in 2010, including: 1) "Hello Health" franchised primary care practices with online tools and direct payments, 2) use of surgical checklists to improve safety, 3) mobile health applications like HealthMap for disease surveillance, 4) direct-to-consumer genetic testing providing personalized health information, 5) "reverse innovations" developed first for emerging markets, 6) services generating personalized care plans from health data, 7) point-of-care diagnostic technologies, 8) the University of Toronto's crowdsourcing of health system ideas, 9) the growth of mobile health applications, and 10) patient data sharing communities like PatientsLikeMe. These innovations aim to improve health
Pistoia Alliance European Conference 2015 - Ann Martin / IMI
Slides from a presentation given at the Pistoia Alliance European Conference 2015, in Zurich, Switzerland.
Similar to Development of drugs in public-private partnership (PPP) environments (20)
GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...
GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...
A white paper on Collaborative Drug Discovery: The Rising Importance of Rare ...
A white paper on Collaborative Drug Discovery: The Rising Importance of Rare ...
Evolving markets require evolving market approaches
Evolving markets require evolving market approaches
Working in Global HealthChapter 18Chapter 18 Working i
Working in Global HealthChapter 18Chapter 18 Working i
Pistoia Alliance European Conference 2015 - Ann Martin / IMI
Pistoia Alliance European Conference 2015 - Ann Martin / IMI
Recently uploaded
Zodiac Signs and Food Preferences_ What Your Sign Says About Your Taste
Know what your zodiac sign says about your taste in food! Explore how the 12 zodiac signs influence your culinary preferences with insights from MyPandit. Dive into astrology and flavors!
3 Simple Steps To Buy Verified Payoneer Account In 2024
Buy Verified Payoneer Account: Quick and Secure Way to Receive Payments
Buy Verified Payoneer Account With 100% secure documents, [ USA, UK, CA ]. Are you looking for a reliable and safe way to receive payments online? Then you need buy verified Payoneer account ! Payoneer is a global payment platform that allows businesses and individuals to send and receive money in over 200 countries.
If You Want To More Information just Contact Now:
Skype: SEOSMMEARTH
Telegram: @seosmmearth
Gmail: seosmmearth@gmail.com
Organizational Change Leadership Agile Tour Geneve 2024
Organizational Change Leadership at Agile Tour Geneve 2024
Recruiting in the Digital Age: A Social Media Masterclass
In this masterclass, presented at the Global HR Summit on 5th June 2024, Luan Wise explored the essential features of social media platforms that support talent acquisition, including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok.
buy old yahoo accounts buy yahoo accounts
As a business owner, I understand the importance of having a strong online presence and leveraging various digital platforms to reach and engage with your target audience. One often overlooked yet highly valuable asset in this regard is the humble Yahoo account. While many may perceive Yahoo as a relic of the past, the truth is that these accounts still hold immense potential for businesses of all sizes.
2022 Vintage Roman Numerals Men Rings
Discover timeless style with the 2022 Vintage Roman Numerals Men's Ring. Crafted from premium stainless steel, this 6mm wide ring embodies elegance and durability. Perfect as a gift, it seamlessly blends classic Roman numeral detailing with modern sophistication, making it an ideal accessory for any occasion.
https://rb.gy/usj1a2
Mastering B2B Payments Webinar from BlueSnap
B2B payments are rapidly changing. Find out the 5 key questions you need to be asking yourself to be sure you are mastering B2B payments today. Learn more at www.BlueSnap.com.
An introduction to the cryptocurrency investment platform Binance Savings.
Learn how to use Binance Savings to expand your bitcoin holdings. Discover how to maximize your earnings on one of the most reliable cryptocurrency exchange platforms, as well as how to earn interest on your cryptocurrency holdings and the various savings choices available.
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka➒➌➎➏➑➐➋➑➐➐Dpboss Matka Guessing Satta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka Indian satta Matka Dpboss Matka Kalyan Chart Matka Boss otg matka Guessing Satta Industrial Tech SW: Category Renewal and Creation
Every industrial revolution has created a new set of categories and a new set of players.
Multiple new technologies have emerged, but Samsara and C3.ai are only two companies which have gone public so far.
Manufacturing startups constitute the largest pipeline share of unicorns and IPO candidates in the SF Bay Area, and software startups dominate in Germany.
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdf
In the recent edition, The 10 Most Influential Leaders Guiding Corporate Evolution, 2024, The Silicon Leaders magazine gladly features Dejan Štancer, President of the Global Chamber of Business Leaders (GCBL), along with other leaders.
Call 8867766396 Satta Matka Dpboss Matka Guessing Satta batta Matka 420 Satta...
CALL 8867766396 SATTA MATKA | DPBOSS | KALYAN MAIN BAZAR | FAST MATKA | DPBOSS GUESSING | TARA MATKA | KALYAN CHART | MATKA BOSS
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...
Explore the fascinating world of the Gemini Zodiac Sign. Discover the unique personality traits, key dates, and horoscope insights of Gemini individuals. Learn how their sociable, communicative nature and boundless curiosity make them the dynamic explorers of the zodiac. Dive into the duality of the Gemini sign and understand their intellectual and adventurous spirit.
ModelingMarketingStrategiesMKS.CollumbiaUniversitypdf
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
Understanding User Needs and Satisfying Them
https://www.productmanagementtoday.com/frs/26903918/understanding-user-needs-and-satisfying-them
We know we want to create products which our customers find to be valuable. Whether we label it as customer-centric or product-led depends on how long we've been doing product management. There are three challenges we face when doing this. The obvious challenge is figuring out what our users need; the non-obvious challenges are in creating a shared understanding of those needs and in sensing if what we're doing is meeting those needs.
In this webinar, we won't focus on the research methods for discovering user-needs. We will focus on synthesis of the needs we discover, communication and alignment tools, and how we operationalize addressing those needs.
Industry expert Scott Sehlhorst will:
• Introduce a taxonomy for user goals with real world examples
• Present the Onion Diagram, a tool for contextualizing task-level goals
• Illustrate how customer journey maps capture activity-level and task-level goals
• Demonstrate the best approach to selection and prioritization of user-goals to address
• Highlight the crucial benchmarks, observable changes, in ensuring fulfillment of customer needs
Recently uploaded (20)
Zodiac Signs and Food Preferences_ What Your Sign Says About Your Taste
Zodiac Signs and Food Preferences_ What Your Sign Says About Your Taste
3 Simple Steps To Buy Verified Payoneer Account In 2024
3 Simple Steps To Buy Verified Payoneer Account In 2024
Organizational Change Leadership Agile Tour Geneve 2024
Organizational Change Leadership Agile Tour Geneve 2024
Recruiting in the Digital Age: A Social Media Masterclass
Recruiting in the Digital Age: A Social Media Masterclass
An introduction to the cryptocurrency investment platform Binance Savings.
An introduction to the cryptocurrency investment platform Binance Savings.
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdf
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdf
Call 8867766396 Satta Matka Dpboss Matka Guessing Satta batta Matka 420 Satta...
Call 8867766396 Satta Matka Dpboss Matka Guessing Satta batta Matka 420 Satta...
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...
ModelingMarketingStrategiesMKS.CollumbiaUniversitypdf
ModelingMarketingStrategiesMKS.CollumbiaUniversitypdf
Training my puppy and implementation in this story
Training my puppy and implementation in this story
Development of drugs in public-private partnership (PPP) environments
- 1. Development of drugs in public-private partnership (PPP) environments Marija Mavar Haramija / Nathaniel Stanley / Pascal Maugeri April 2011 MSc Bioinfo - Computer Assisted Drug Discovery
- 5. The Old Method A long and costly process
- 20. New Drugs market entry by disorder and primary indication Source: Christopher P. Adams and Van V. Brantner. Estimating The Cost Of New Drug Development: Is It Really $802 Million? Health Affairs, 25, no.2 (2006):420-428
- 21. The example of Malaria WHO Malaria Report 2008 Estimated incidence of malaria per 1000 population, 2006
- 22. Grants 4 Targets Distribution of applications received National distribution of applications received, (RoW, Rest of the World)
Editor's Notes
- PARASITE
- PM= performance management
- TDR - 2 main goals: Research and development into new and improved approaches on diseases of poverty. Empowering and building research capacity in the countries where the diseases are prevalent. TDR - 1975 MMV - 1999 GATB - 2000 DNDi - 2003 IOWH - 2001 all are working on several (10) projects, developing new drugs that will be affordable and accessible